Our Mission is to Help Save Lives
in the Battle Against Cancer

KinaSense develops products for testing new cancer drugs in the pre-clinical and clinical phases of drug discovery. We strive to be on the forefront of precision medicine by developing next generation diagnostic products for personalizing cancer patient care.

Solutions

Cancer Diagnostics

Tyrosine kinase inhibitors (TKIs) are used to treat a variety of cancer types. The current diagnostic tools lack the predictive power to match the right patient with the right TKI. KinaSense is developing technologies that can be used to predict whether a given patient will benefit from a specific TKI.

Drug Discovery

KinaSense is leveraging its intellectual property to develop assays for in vitro and cell-based kits for measuring TKI efficacy and selectivity. Our unique platform allows measurement of endogenous kinase activity in live cells, bridging the gap between in vitro biochemical and cell-based phenotypic measurements.

Technology

Intellectual Property

KinaSense holds an exclusive license to a technology for detection of tyrosine kinase activity from Purdue Research Foundation.

Products

In vitro and cell-based kinase activity kits for primary or secondary compound library screening

Clinical Research and Development

KinaSense is currently performing proof of concept studies for applying its technologies to advanced renal cell carcinoma.

Members

  • Steven Ouellette, PhD Chief Technology Officer / Co-founder

    Dr. Ouellette is leading the KinaSense effort through business and product development decisions as the Chief Technology Officer. He holds a Ph.D. in Medicinal Chemistry and Molecular Pharmacology from Purdue University, with specialization in bioassay development, cancer biology, and molecular signaling. Steve has worked extensively with cell-based kinase activity assays using the KinaSense core technology.

  • Laurie Parker, PhD Scientific Advisor / Co-founder

    KinaSense core technology was invented in Dr. Parker’s lab at Purdue University in the Department of Medicinal Chemistry and Molecular Pharmacology. She is an inventor and has expertise in synthetic chemistry, bioassay design, and proteomics, and is scientific advisor to KinaSense. Laurie is currently Assistant Professor at University of Minnesota in the Department of Biochemistry, Molecular Biology and Biophysics.

  • Andrew Lipchik, PhD Scientific Advisor / Co-founder

    Dr. Lipchik is a primary inventor of the KinaSense core technology and a scientific advisor to KinaSense. He holds a Ph.D. from the Department of Medicinal Chemistry and Molecular Pharmacology at Purdue University. Andrew is currently doing post-doctoral research at Stanford University in the lab of Michael Snyder.

Partners

  • Purdue Foundry

    KinaSense is a client company of the Purdue Foundry. The Foundry provides business development advice regarding strategy, relations, accounting, and opportunities. The Foundry serves over 15 client companies based on Purdue University developed technology, and is an entrepreneurial hotspot in the Lafayette/West Lafayette, IN region.

  • Horizon BioAdvance

    Horizon BioAdvance is a biomedical research company in Lafayette, IN. They provide assistance in investor relations, business development, and clinincal strategy for KinaSense. Their medical oncologist is Wael Harb, MD, who has extensive experience in cancer drug clinical trials.

  • 1281 Win Hentschel Blvd.
  • West Lafayette, IN 47906
  • info@kinasense.com
  • Copyright © KinaSense 2014. All Rights Reserved.